A J&J spokeswoman said on Monday that the company was still in talks with the South African government and was committed to making its vaccine available at a not-for-profit price.
Pfizer did not immediately respond to a request for comment on Monday but told Reuters last week it sought indemnity and liability protections in all its agreements, consistent with local laws.
J&J and Pfizer will supply South Africa with a combined 61 million vaccine doses, helping to ramp up immunisations after a slow start.
To date, South Africa has vaccinated roughly 290,000 health workers with J&J's one-dose vaccine in a research study, but last week it paused the study while regulators interrogate a possible link between J&J's vaccine and rare cases of blood clots.
The government expects the first commercial batch of J&J doses later this month and doses of Pfizer's two-shot vaccine next month.
Between the J&J and Pfizer deals, South Africa has secured enough vaccines for 46 million of its roughly 60 million people.
In the 2021 budget presented in February, the government said it could spend up to 19.3 billion rand over three fiscal years on its vaccination programme.